<DOC>
	<DOCNO>NCT01260675</DOCNO>
	<brief_summary>Phase 1 study determine pharmacokinetic profile NanoBUP Capsules Suboxone .</brief_summary>
	<brief_title>Study Assess PK Profile NanoBUP Capsules Relative Suboxone</brief_title>
	<detailed_description>The pharmacokinetics orally administer investigational buprenorphine hydrochloride/naloxone hydrochloride 2 mg/0.5 mg capsule formulation study . This single-dose , two period , two treatment , crossover comparative bioavailability study fast condition .</detailed_description>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>Subject must male nonpregnant , nonbreastfeeding female . Subject must 18 55 year age ( inclusive ) . Subject 's Body Mass Index ( BMI ) must 18 30 kg/m2 ( inclusive ) , subject must weigh minimum 50 kg ( 110 lb ) . Female subject surgically sterile least 6 month least 2 year postmenopausal must agree utilize one follow form contraception , sexually active male partner , screen completion study . Approved forms contraception abstinence , hormonal ( oral , implant , transdermal , vaginal , injection ) use least 3 consecutive month prior first dose study medication , double barrier ( condom spermicide ; diaphragm spermicide ) , intrauterine device ( IUD ) , vasectomized partner ( 6 month minimum since vasectomy ) . Subject must voluntarily consent participate study provide write informed consent prior start studyspecific procedure . Subject willing able remain study unit entire duration confinement period return outpatient visit History presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , metabolic , dermatologic , neurologic , oncologic , psychiatric disease condition , opinion Investigator , would jeopardize safety subject validity study result . A clinically significant abnormal find physical exam , medical history , ECG , clinical laboratory result screen . History presence allergic adverse response buprenorphine , naloxone , naltrexone , opioids , comparable similar product . Been significantly abnormal diet 4 week precede first dose study medication . Donated blood plasma within 30 day prior first dose study medication . Participated another clinical trial within 30 day prior first dose study medication . Used overthecounter ( OTC ) medication , include nutritional supplement , within 7 day prior first dose study medication . Used prescription medication , except hormonal contraceptive hormonal replacement therapy , within 14 day prior first dose study medication . Has treat know enzyme alter drug , barbiturate , phenothiazine , cimetidine , carbamazepine , etc. , within 30 day prior first dose study medication . Smoked used tobacco product within 60 day prior first dose study medication . History substance abuse dependence ( include alcohol , opioids , intravenous drug abuse ) Is female positive pregnancy test result . A positive urine screen drug abuse ( amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) . A positive urine alcohol test screen positive ethanol breath test checkin study period consume alcohol within 48 hour prior screen checkin study period . Had positive test , treat hepatitis B , hepatitis C , HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>phase 1 study</keyword>
	<keyword>volunteer</keyword>
</DOC>